Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate Health Canada, Ottawa, Ontario, Canada.
Vaccine. 2013 Aug 12;31(36):3702-11. doi: 10.1016/j.vaccine.2013.05.098. Epub 2013 Jun 10.
Quantitative determination of the individual polysaccharide components in multivalent meningococcal vaccines is an important step in manufacturing and regulatory control. Current methods are complicated due to the use of multiple chromatographic setups and/or other analytical techniques for the four meningococcal serogroup polysaccharides (A, C, Y, W135). In addition, different methods are sometimes used depending on whether or not the polysaccharide is conjugated to a carrier protein. In an effort to simplify such analyses, hydrolysis conditions were determined for the optimal yield of each characteristic saccharide from the respective repeating units. One condition was identified for mannosamine-6-phosphate from MenA, one for neuraminic acid from MenC, and one for both glucose and galactose from MenY and MenW135, respectively. These conditions, initially assessed for monovalent solutions, were then confirmed for a quadrivalent solution. The monosaccharide products were separated, identified and quantitated using a single HPAEC-PAD protocol, with a customised multi-stage linear gradient eluent profile and one column setup, for determination of all four serogroup components. Comparison to calibration curves constructed from sets of monosaccharide or hydrolysed polysaccharide standards allowed for the quantitation of each characteristic serogroup monosaccharide in polysaccharide and polysaccharide-conjugate vaccines. When required, molecular size separation using a non-cellulosic centrifugal filter device effectively removed all interfering saccharide excipient without loss of serogroup polysaccharides. These methods were used to analyse multiple lots of a number of different monovalent or multivalent real polysaccharide-based vaccine products, in liquid or lyophilised powder formulations, with or without excipients. The methods were demonstrated to be highly reproducible and very useful for the evaluation of antigen content and lot-to-lot consistency of manufacture. The methods described here represent an increase in precision, level of accuracy and efficiency compared to current methods, and may be adaptable for evaluation of other types of polysaccharide-based vaccines.
定量测定多价脑膜炎球菌疫苗中的各个多糖成分是制造和监管控制的重要步骤。由于需要使用多种色谱设置和/或其他分析技术来分析四种脑膜炎球菌血清群多糖(A、C、Y、W135),因此当前的方法比较复杂。此外,根据多糖是否与载体蛋白结合,有时会使用不同的方法。为了简化此类分析,确定了每种特征性糖从各自重复单元中获得最佳产量的水解条件。确定了一种条件用于从 MenA 中获得甘露糖-6-磷酸,一种条件用于从 MenC 中获得唾液酸,一种条件用于从 MenY 和 MenW135 中分别获得葡萄糖和半乳糖。这些条件最初在单价溶液中进行评估,然后在四价溶液中得到证实。使用单 HPAEC-PAD 方案分离、鉴定和定量单糖产物,该方案使用定制的多阶段线性梯度洗脱轮廓和一个柱设置,用于测定所有四个血清群成分。与由单糖或水解多糖标准品集构建的校准曲线进行比较,允许定量多糖和多糖缀合物疫苗中每个特征性血清群单糖。当需要时,使用非纤维素离心过滤装置进行分子大小分离可有效去除所有干扰性糖赋形剂,而不会损失血清群多糖。这些方法用于分析多种不同单价或多价实际多糖基疫苗产品的多个批次,包括液体或冻干粉末制剂,无论是否有赋形剂。这些方法被证明具有高度重现性,非常有助于评估抗原含量和制造批间一致性。与当前方法相比,这里描述的方法在精度、准确度和效率方面都有所提高,并且可能适用于评估其他类型的多糖基疫苗。